Background-Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk. Methods and Results-We studied the potential for increased risk of adverse cardiovascular events among users of clopidogrel with versus without concurrent use of PPIs in 3 large cohorts of patients Ն65 years of age, treated between 2001 and 2005. All patients had undergone percutaneous coronary intervention or had been hospitalized for acute coronary syndrome in Pennsylvania, New Jersey, or British Columbia, and subsequently had initiated treatment with clopidogrel. We recorded myocardial infarction hospitalization, death, and revascularization among PPI users and nonusers. We assessed our primary end point of myocardial infarction hospitalization or death using cohort-specific and pooled regression analyses. We entered 18 565 clopidogrel users into our analysis. On a pooled basis, 2.6% of those who also initiated a PPI versus 2.1% of PPI nonusers had a myocardial infarction hospitalization; 1.5% versus 0.9% died; and 3.4% versus 3.1% underwent revascularization. The propensity score-adjusted rate ratio for the primary end point of myocardial infarction or death was 1.22 (95% confidence interval, 0.99 to 1.51); for death, 1.20 (95% confidence interval, 0.84 to 1.70); and for revascularization, 0.97 (95% confidence interval, 0.79 to 1.21). Matched analyses generally yielded similar results. Conclusions-Although point estimates indicated a slightly increased risk of myocardial infarction hospitalization or death in older patients initiating both clopidogrel and a PPI, we did not observe conclusive evidence of a clopidogrel-PPI interaction of major clinical relevance. Our data suggest that if this effect exists, it is unlikely to exceed a 20% risk increase.
T he role of clopidogrel after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) is well established by large-scale clinical trials, meta-analyses, and clinical practice guidelines. [1] [2] [3] [4] [5] [6] [7] As a result, the use of clopidogrel has risen sharply since its initial marketing in 1997 8 ; it is now the second-best-selling drug in the world. 9 Given the speed at which the drug has been adopted, the full range of potential interactions between clopidogrel and other agents has yet to be fully explored.
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A proton pump inhibitor (PPI) is frequently coprescribed with clopidogrel to reduce the risk of gastrointestinal bleeding. There has been little research evaluating the benefits of this strategy, 10 and no specific guidelines are in place for the use of gastroprotective agents in patients receiving clopidogrel. As a result of concerns that the antiplatelet effects of clopidogrel could be diminished by the concurrent use of PPIs, [11] [12] [13] questions have recently been raised about the safety of the drug combination. 14 These concerns are attributed to the competitive inhibition by PPIs of one of the cytochrome P450 isoenzymes, CYP2C19, involved in the metabolic activation of clopidogrel. This effect is thought to be a mechanism of "clopidogrel resistance" in such patients. [15] [16] [17] The clinical consequences of a potential clopidogrel-PPI interaction remain largely unclear but could be of considerable importance. Two studies have shown an increased risk of acute cardiovascular events or death with this combination, 18, 19 but they may have overestimated the risk as a result of incomplete control of confounding and biased patient selection. We conducted a retrospective study in 3 large healthcare use databases sought to address study design issues and confounding. We identified cohorts of patients who had undergone PCI or had ACS. Adjusting for confounding factors using both standard and newly introduced approaches, we examined whether there was a higher rate of certain adverse outcomes in patients taking clopidogrel who were treated concurrently with PPI versus those taking clopidogrel alone. The outcomes studied were myocardial infarction (MI) hospitalization, revascularization, and death.
Methods

Sources of Data
We pooled data from patients enrolled in 3 large health insurance programs: the provincial health care system funded by the British Columbia government; the Pharmaceutical Assistance Contract for the Elderly in Pennsylvania; and the Pharmaceutical Assistance to the Aged and Disabled in New Jersey. The British Columbia database linked information from PharmaNet, which captures essentially all medications dispensed to all patients in the province 20 ; its Medical Services Plan and hospital discharge files, which together cover virtually all clinical encounters; and the province's vital statistics database. The Pennsylvania and New Jersey databases were made up of those states' drug benefit programs data linked with complete claims data from Medicare Parts A and B, including hospital discharge information and all fee-for-service charges, and with vital status information from the Social Security Administration's Death Master File.
The Pennsylvania and New Jersey pharmacy assistance programs served low-income adults Ն65 years of age; these programs provided generous pharmaceutical benefits for a modest copayment. Owing to the low cost, unrestricted formularies, low turnover, and the fact that drug claims were recorded for purpose of payment to dispensing pharmacies, capture of out-of-hospital prescription drug use is relatively complete. British Columbia's program is available to all residents of the province, and PharmaNet records all out-ofhospital prescription drug dispensing independently of whether the drugs are paid for by the program or by the patient, or are dispensed in person or by mail. Throughout the study period, British Columbia had a prior authorization program in place for clopidogrel. Underreporting and misclassification are minimal because of the electronic data entry of all drug dispensings. 20 All traceable personal identifiers were removed from the data sets before analysis to protect patient confidentiality. The Institutional Review Board of the Brigham and Women's Hospital approved this study. Data use agreements were in place.
Study Population
We identified all patients who underwent PCI or were hospitalized for ACS in British Columbia from January 1, 2001, to December 31, 2005 , and in Pennsylvania and New Jersey from January 1, 2001, to July 31, 2005 . PCI was defined by procedure codes recorded. ACS was defined as a hospitalization with a primary discharge code for MI or unstable angina; we required that the hospitalization last at least 3 days and no more than 180 days. For further details, see the Appendix in the online-only Data Supplement. If patients had several events during this time, we included only the first as the index event. To minimize age heterogeneity among the 3 cohorts, we restricted British Columbia patients to those Ն65 years of age.
Patients became eligible for this study the day after discharge for PCI or ACS or the day after outpatient PCI ( Figure 1 ). We limited our study cohorts to new users of clopidogrel: those who did not fill any prescriptions for clopidogrel in the 180 days before the index event and then both survived the first 7 days after the index event and initiated clopidogrel within those 7 days. 21 To ensure uniform eligibility, all study subjects were required to have used at least 1 medical service and to have filled at least 1 prescription in each of the two 6-month periods preceding the index event.
Initial PPI Exposure Status
The exposure of interest was use of a PPI, defined as omeprazole, esomeprazole, lansoprazole, pantoprazole, or rabeprazole, dispensed at any point 21 days before and/or within 7 days after the index event, and dispensed with sufficient supply of the drug to last through the 7 days after the index event. Follow-up began for all patients on the day after this 7-day exposure assessment run-in period. The run-in period equally allowed all patients to be on PPI therapy or to be categorized as PPI nonusers; therefore, the study is not subject to immortal time bias. 22 In the United States, omeprazole was available over the counter during some of the study period, but for the patients in our population, the price would have been higher than the copayment in the state drug plans. In Canada, no PPI was available over the counter.
Study End Points
We measured the occurrence of 3 study end points over up to 180 days of follow-up: MI hospitalization, revascularization, and death resulting from any cause. A combined MI hospitalization and death outcome was our primary end point. We defined MI as above and allowed the code to appear in the secondary position. 23 Revascularization was assessed as a PCI or coronary artery bypass graft surgery at any time during follow-up (see the Appendix in the online-only Data Supplement). Death was assessed through vital statistics and government agencies.
Patient Characteristics
With respect to patients' characteristics, we recorded age, sex, and calendar year of study entry. In Pennsylvania and New Jersey, we recorded a binary variable for nonwhite race; race is not measured in British Columbia. Over the 365 days before the index event, we assessed patients' prescription drug use, reported comorbidities, and intensity of medical service use (see the Appendix in the online-only Data Supplement). We computed a Charlson comorbidity score. 24 We measured the length of stay during the care for the index event (Ն1 days) and whether an MI occurred and/or a PCI was performed during that period.
Statistical Analysis
We estimated the rate ratio (RR) comparing the incidence of the study outcomes among clopidogrel users who also used PPIs and those who were PPI nonusers. Multivariate-adjusted RRs were estimated by the use of Cox proportional-hazards regression. In this "as-treated" analysis, patients were censored at the earliest of time of outcome event, at the end of 180 days, at 5 days after stopping clopidogrel, or at death. In addition, PPI-exposed patients were censored 5 days after stopping a PPI, and PPI nonuser patients were censored on the day of starting a PPI. If an outcome occurred on the day of censoring, the outcome was assumed to take place before the censoring event. In all cases, drug starting and stopping were computed from pharmacy claims data using the date of fill and the reported days supplied. We analyzed the data separately within each of the 3 regional databases (British Columbia, Pennsylvania, New Jersey) and then, after pooling all cohorts, with the pooled regression models stratified by database. We computed 95% confidence intervals (CIs).
Because information content differed from database to database, we applied a high-dimensional propensity score (hd-PS) to further improve confounding adjustment. 25 The technique has been shown to provide equally valid or more valid estimates of treatment effects by adjusting for hundreds of confounders identified empirically from databases. In our study, the hd-PS algorithm examined all drugs, diagnosis codes, and procedure codes reported for a patient and identified the 400 codes that, if adjusted for, had the most potential to reduce bias. We entered these 400 codes into a propensity score along with the confounders that we identified a priori. The PS was ranked by deciles within each database and then indicators for decile were entered into the Cox model. 26 As a first sensitivity analysis, we matched the cohorts using 1:1 greedy matching on the hd-PS. 27 Additionally, we performed an analysis in which we reduced the maximum duration of follow-up to 90 days. We then performed a "PPI new user" analysis in which we excluded patients who had a current PPI prescription at the time of the index event or who had filled a PPI prescription in the previous 180 days. To assess whether individual PPIs differed with respect to an interaction with clopidogrel, we performed agent-specific analyses among omeprazole and pantoprazole users. We also performed a cumulative-risk, intention-to-treat analysis in which the PPI exposure was carried forward through a fixed 90-day follow-up period. Finally, we tested whether PPI users were at greater risk of death or MI regardless of their use of clopidogrel. In this analysis, we allowed clopidogrel nonusers to enter the cohorts, censored patients on the day a PPI nonuser started PPI therapy or 5 days after a PPI user stopped the PPI, and adjusted for clopidogrel use.
Results
Of the 64 561 patients in our cohorts who underwent PCI or hospitalization for ACS between 2001 and 2005, 31% had any recorded use of clopidogrel in the 7 days after their hospital discharge, 40% in the 90 days after discharge, and 45% in the 180 days after discharge. We found that 18 565 (29%) survived at least 7 days after the event or procedure, were prescribed clopidogrel during those 7 days, met the study inclusion criteria, and were therefore included in our analytical cohorts ( Figure 2 ). There were differences in the baseline characteristics among the 3 regional cohorts, although the Pennsylvania and New Jersey cohorts showed many similarities. Average age was 74 years in British Columbia (range, 65 to 100 years) and 78 years in Pennsylvania and New Jersey (range, 65 to 104 years in Pennsylvania and 65 to 101 years in New Jersey; Table 1 ). As a result of the patients' age and the income restrictions of the programs, 75% of the patients in Pennsylvania and 65% in New Jersey were female compared with 37% in British Columbia. The prevalence of baseline risk factors also ranged widely; eg, both history of gastrointestinal bleeding and hemorrhagic strokes before the cohort-defining event were more common in New Jersey and Pennsylvania than in British Columbia. PPI users generally had more comorbidities than did their nonuser counterparts.
The crude incidence rate of MI hospitalization or death was 27.7 events per 100 person-years in British Columbia, 29.9 in Pennsylvania, and 27.6 in New Jersey. Death occurred during follow-up in 0.6% of the British Columbia cohort, 1.5% of the Pennsylvania cohort, and 1.6% of the New Jersey cohort. Additional patients died during the 7-day run-in period ( Figure 2 ). Across all databases and outcomes, the median length of follow-up was 29 to 30 days among the PPI users and nonusers ( Table 2) ; 2% of patients were followed up for the maximum 180 days. Among our 3 cohorts of clopidogrel users, crude rates of MI hospitalization or death were substantially higher for PPI users than PPI nonusers. The pooled crude RR was 1.74 (95% CI, 1.44 to 2.10); with multivariate adjustment, the RR fell to 1.32 (95% CI, 1.08 to 1.61). With hd-PS adjustment, it fell again to 1.22 (95% CI, 0.99 to 1.51; Table 3 ). For revascularization, results varied significantly among the cohorts (P for heterogeneity Ͻ0.01), ranging from an RR of 0.70 (95% CI, 0.50 to 0.99) in New Jersey to 1.64 (95% CI, 1.15 to 2.35) in British Columbia. Between the PPI user and nonuser groups, there was overall NSAID indicates nonsteroidal antiinflammatory drug; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker. Cohort entry was defined by PCI or ACS followed by new use of clopidogrel within 7 days of hospital discharge. Follow-up started with the day after the fixed 7-day exposure assessment period.
*PPI use is defined as a prescription for a PPI in the 21 days before hospital admission and/or the 7 days after discharge. PPIs included in the analysis were omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole.
†Race was not measured in British Columbia.
balance of the PS and the measured covariates within the decile strata of the score. Matching on hd-PS resulted in smaller (82% of exposed patients) but broadly balanced treatment groups in each cohort; eg, PPI user and nonuser ages were equivalent to the first decimal place. Overall, the results based on the matched populations (Table 4 ) were similar to those based on the unmatched populations. The matched RR for MI hospitalization or death was 1.26 (95% CI, 0.97 to 1.63).
The sensitivity analysis in which we limited follow-up to 90 days included 92% of the primary study population and yielded results substantially similar to those of the primary analysis; the pooled hd-PS-adjusted RR for MI hospitalization or death was 1.23 (95% CI, 1.00 to 1.53). Similarly, when we included only new PPI users, we observed this RR to be 1.11 (95% CI, 0.81 to 1.52). The sensitivity analysis in which the exposure was carried forward through a fixed 90-day follow-up period yielded results closer to the null than did the primary analysis (Table I of the online-only Data Supplement); the RR was 1.06 (95% CI, 0.91 to 1.23). Extending the run-in period from 7 to 15 days allowed more time for patients to become exposed, but starting follow-up on day 16 excluded events that occurred in the early days after the index event; the RR moved to 1.38 (95% CI, 1.12 to 1.69). The analyses in which we assessed the omeprazole and pantoprazole user groups were substantially similar both to each other and to the primary analysis; the RR of MI hospitalization or death in the omeprazole-only study was 1.17 (95% CI, 0.68 to 2.01) and in the pantoprazole-only study was 1.26 (95% CI, 0.93 to 1.71). Our study of risk from PPI use regardless of clopidogrel use yielded results that were null or protective after adjustment. The pooled hd-PS-adjusted RR of MI hospitalization or death associated with PPI use itself among the 61 605 patients in this analysis was 0.79 (95% CI, 0.73 to 0.85) and 1.02 (95% CI, 0.93 to 1.12) for MI hospitalization alone.
Discussion
Recent trial and nonexperimental studies have reported that an interaction between PPIs and clopidogrel increases the risk for a second MI by up to 40%, which, if substantiated, would be of major clinical and public health importance. In the study presented here, we applied traditional and more advanced confounding control techniques to an analysis of 18 565 North American patients in 3 cohorts. The patients were adults Ն65 years of age who had recently undergone PCI or an ACS hospitalization. To the best of our knowledge, ours is the largest study of this question to date. Although the point estimates we observed in each of the 3 cohorts indicated a slightly increased risk of MI hospitalization or death in older patients initiating both clopidogrel and a PPI, the possible increase in risk was modest, the confidence intervals were wide, and we did not observe consistent evidence of a substantial or statistically significant clopidogrel-PPI interaction. Progressively better control of con- founding reduced the apparent risk from the initial crude estimates, suggesting that some or all of the final observed risk may have been the result of residual unmeasured confounding. Our data suggest that if a true interaction does exist, its effect is unlikely to exceed a 20% risk increase.
In both of the recently published studies evaluating the interaction between clopidogrel and PPIs, 18, 19 patients who received PPIs had more comorbidity than those prescribed clopidogrel alone, leading to a concern about confounding by indication. 28 For example, physicians may be more likely to use gastroprotective drugs in frailer patients, eg, those started on a PPI during an intensive care unit stay, or in smokers, who have a higher incidence of upper gastrointestinal disease. Conventional adjustment as used by Ho et al 19 al 18 may inadequately account for confounding in this treatment group. In our study, we performed more extensive confounding adjustment 25 and verified in a sensitivity analysis that after adjustment, the PPI users were not more likely to be at increased risk for MI or death. Further complicating the interpretation of the Ho et al results is their inclusion of immortal person time in the study's primary analysis. 22 This design results in bias caused by the fact that exposure status was determined during follow-up; those who were sickest and had an MI early in follow-up would have had a lower chance of being exposed, and consequently, unexposed patients would have been oversampled. Our study design avoided such biases by starting follow-up only after a 7-day run-in period during which exposure status was determined for all patients. The possibility of a modest risk posed by a PPI-clopidogrel interaction would be consistent with the findings of the randomized study by Gilard et al 12 in which omeprazole partially reduced the inhibitory effect of clopidogrel as assessed by tests of platelet activity. The correlation between the results of the assay used by these investigators and subacute coronary stent thrombosis has been previously observed. 29 Separately, 2 other recent studies reported that patients with substantial loss-offunction mutations in the metabolic pathway that activates clopidogrel (CYP2C19) 16, 17 have a doubling of risk of coronary events. CYP2C19 is also the putative mechanism by which clopidogrel and PPIs interact.
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If PPIs do indeed reduce the beneficial effect of clopidogrel, then 20% may well be the upper bound for any increase in the relative risk of MI or death. In post-PCI or ACS patients using clopidogrel, the baseline risk of the outcome is high. If absolute risk increases are constant, relative risks are smaller in those patients with high baseline risk. 30 Furthermore, the Gilard et al 12 study indicated only a partial reduction in the antiplatelet action of clopidogrel; ie, even with a drug-drug interaction, clopidogrel would still provide some benefit. Finally, the CYP2C19 polymorphism, which is likely equally prevalent in the PPI user and nonuser groups, itself reduces the protective effect of clopidogrel in a certain fraction of the population. This attenuation would yield a decrease in relative risk compared with a hypothetical population in which nobody carried the allele.
To the extent possible in our nonrandomized study, we drew on the design principles of a randomized controlled trial: We limited the patient population to those who were clopidogrel naïve, instituted a 7-day run-in period, and started follow-up only from the time that the patient's exposure status had been fully determined. To minimize the effects of unmeasured confounding, particularly confounding caused by the "channeling" to 1 treatment or another in response to disease severity and patient prognosis, 28 we adjusted by an hd-PS. Adjusting for or matching on a PS that includes all pertinent confounders should serve a role analogous to randomization in a randomized controlled trial 26 ; the hd-PS method allowed us to enrich the standard PS with more pertinent confounders than are possible to specify a priori. The hd-PS we adjusted for included our investigator-identified covariates along with 400 additional variables empirically identified from the claims codes in our databases. It therefore allowed more confounding adjustment than did standard PS or multivariate analysis. One confounder that remained unmea-sured was aspirin use, although in this population of patients who have all had cardiac events, aspirin would have been indicated for and likely used by almost all members of the cohort and thus would be a weak confounding factor.
In the United States, omeprazole has been available over the counter since June 2003; as a result, our study may be open to some misclassification of exposure. In Pennsylvania and New Jersey, however, the low-income patient population we studied would have little incentive to buy PPIs over the counter because their copayment for prescription PPIs was less than half of the 2008 over-the-counter prices. 31 In Canada, PPIs are not available over the counter, although it is possible that British Columbia residents purchased over-the-counter PPIs in the United States, and yet the British Columbia data reflected the same findings as New Jersey and Pennsylvania data. With respect to potential misclassification of the outcomes, the hard end point of MI hospitalization or death was defined in a highly specific and nondifferential way; such specificity should lead to a nonexistent or negligible misclassification bias in relative risk. 32 Conversely, the discretion involved in choosing patients on whom to perform a revascularization procedure likely explains at least some of the heterogeneity of the revascularization results; very sick patients are less likely to receive such treatment because of the overall risk-benefit assessment. 33, 34 
Conclusions
The results of this large study of community-dwelling patients Ն65 years of age followed up after PCI or ACS failed to demonstrate a large or statistically significant increase in the relative risk of MI hospitalization or death owing to concurrent use of clopidogrel and PPIs, as previously reported. Our data, however, are consistent with the possibility of an interaction with only modest clinical effect in the routine care of older adults.
